Bluejay Diagnostics, Inc. BJDX
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -77.98%
- 1 year
- -90.76%
- Market cap
- 2.62M
- EPS (ttm)
- -14.32
- Shares out
- 552.85K
- Forward P/E
- -11.88
- YTD return
- -77.98%
- 1-year return
- -90.76%
- Volume
- 16.93K
- Avg volume
- 338.00K
- Open
- 2.22
- Previous close
- 2.19
- Day's range
- 2.22 – 2.41
- 52-week range
- 2.12 – 27.68
- Beta
- 0.73
- Earnings date
- May 15, 2024
ALL -586,237.65 (-100.00%)
Key statistics
- Enterprise value
- -7.04M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.49M
- Total cash
- 8.06M
- Total debt
- 442.13K
- Return on equity
- -125.25%
- Short % of float
- 0.97%
- 50-day average
- 4.46
- 200-day average
- 96.26
Next earnings
May 15, 2024
Expected May 15, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -8.00 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -256.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -272.00 | -712.00 | -440.00 | -161.76% |
| Nov 9, 2023 | Sep 1, 2023 | -328.00 | -832.00 | -504.00 | -153.66% |
| Aug 14, 2023 | Jun 1, 2023 | -600.00 | -1,100.00 | -500.00 | -83.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 2023 | Dawson James | down | Buy | Neutral |
About Bluejay Diagnostics, Inc.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progression in critical care settings. Further, it develops cardiac biomarkers, such as hsTNT and NT pro-BNP, as well as other tests using the Symphony platform. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- bluejaydx.com
News
Bluejay Diagnostics Announces 1-For-4 Reverse Stock Split, Effective Nov. 3 
Bluejay Diagnostics Completes Establishment Of Manufacturing Site For Symphony Cartridges, Reaching Contractual Milestone As It Advances Toward Regulatory Submission And Potential Commercialization 
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients 
Bluejay Diagnostics Reports SYMON-II Baseline Data Showing Diverse Critically Ill Sepsis Population And Meaningful Mortality Events Supporting IL-6 Evaluation For 28-Day Mortality Risk 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Bluejay Diagnostics And Lovell Announce Distribution, Co-Marketing And Strategic Partnership To Support Introduction Of Bluejay’s Products Into U.S. Federal Healthcare Market
Bluejay Diagnostics Q2 EPS $(1.12) Up From $(5.64) YoY 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on BJDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHASE DONALD R | Director | Stock Award(Grant) | Jan 31, 2023 | 792,852 |
| DEY INDRANIL | Chief Executive Officer | Purchase | Dec 12, 2023 | 233,093 |
| DEY SVETLANA | Director | Purchase | Dec 12, 2023 | 206,067 |
| FISHER KENNETH R | Chief Financial Officer | Stock Award(Grant) | Jan 31, 2023 | 113,184 |
| GEMIGNANI GARY G | Director | Stock Award(Grant) | Jan 31, 2023 | 27,500 |
| WURTH DOUGLAS CLARK | Director | Stock Award(Grant) | Jan 31, 2023 | 2,313,850 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Anson Funds Management LP | 1.16% | 6,386 | 24.27K | Sep 29, 2024 |
| Sabby Management, LLC | 1.10% | 6,104 | 23.20K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.50% | 2,740 | 10.41K | Sep 29, 2024 |
| CVI Holdings, LLC | 0.24% | 1,323 | 5.03K | Jun 29, 2024 |
| UBS Group AG | 0.22% | 1,229 | 4.67K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.19% | 1,053 | 4.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.07% | 403 | 1.53K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.00% | 1 | 3 | Oct 30, 2024 |